查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961064

全球外泌體研究市場：依產品/服務、適應症、應用、終端用戶和地區劃分－市場動態、市場分析、機會和預測（2026-2035 年）

Global Exosome Research Market: By Product & Service, Indication, Application, End User, Region - Market Dynamics, Market Analysis, Opportunity Forecasted For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 242 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄
外泌體研究市場正處於關鍵的轉折點，其特徵是快速成長和不斷擴大的商業潛力。 2025 年，該市場規模約為 2.807 億美元，預計將顯著成長，到 2035 年營收將達到 24.9142 億美元。這一顯著增長反映了 2026 年至 2035 年預測期內 24.4% 的複合年增長率，凸顯了外泌體技術在研究和治療領域日益增長的重要性和應用。 推動這一轉變的關鍵因素之一是已證實臨床療效數據的積累，這增強了外泌體作為有效治療劑的可信度。隨著越來越多的臨床試驗證實了基於外泌體的療法的安全性和治療益處，包括製藥公司、投資者和監管機構在內的利益相關者日益認識到其在滿足未被滿足的醫療需求方面的潛力。同時，可擴展生產技術的進步使得生產數量和品質均符合廣泛商業化分銷要求的外泌體成為可能。

主要市場趨勢

外泌體研究市場的競爭格局清晰地分為兩大類：治療先驅者和產業基礎設施開發商，兩者都在該領域的發展中發揮著至關重要的作用。在治療領域，Capricor Therapeutics 和 Direct Biologics 無疑是業界領導者。 Capricor Therapeutics 的策略優勢源自於其雄厚的財務實力，截至 2025 年，該公司擁有 1.52 億美元的現金儲備。如此強勁的財務狀況確保了公司擁有必要的資源來支持基於外泌體的療法的開發和商業化。

同時，Direct Biologics憑藉其卓越的臨床進展建立了競爭優勢，包括在其III期主要試驗 "EXTINGUISH" 中成功招募了320名患者。此外，該公司還實施了擴大用藥計劃，為103名患者提供了治療，展現了在推動臨床開發和確保患者用藥之間取得的顯著平衡。

在基礎設施方面，Lonza和Bio-Techne作為支撐外泌體研究生態系統的關鍵產業基礎，發揮主導作用。特別是，Lonza已積極確立其作為外泌體治療領域領先的合約開發和生產組織（CDMO）的地位。 Lonza 擴張過程中的一個重要里程碑是收購了 Codiak BioSciences 的外泌體生產設施（位於馬薩諸塞州萊剋星頓），該收購於 2021 年 11 月完成。

核心驅動因素

目前，外泌體研究市場由兩大強勁的需求引擎驅動，它們正在重塑市場發展軌跡並推動快速創新。一方面，對非侵入性 "液體活檢" 生物標誌物的需求迫切且日益增長。這為臨床醫生提供了一種創新的疾病診斷和監測方法，只需簡單的血液檢測和其他體液樣本即可。與傳統的侵入性、高成本且耗時的活檢不同，液體活檢利用外泌體攜帶的獨特分子特徵，能夠早期且高精度地檢測疾病狀況。這種能力在腫瘤學領域尤其重要，因為癌症的早期發現可以顯著改善患者的預後。

新興機會趨勢

影響外泌體研究市場的最重要趨勢之一是工作流程的日益工業化。這標誌著從手動實驗室技術轉向標準化自動化流程的重大轉變。傳統上，外泌體分離被認為是一種“技術”，依賴於勞動密集的手工方法，需要專業知識，並且常常導致批次間差異。如今，這種方法正迅速被高度可重複且可擴展的工作流程所取代，這些工作流程旨在滿足臨床研究和商業生產的嚴格要求。這種轉變清晰地體現在高通量流式細胞儀技術的日益普及上，該技術能夠以更高的準確性和效率對外泌體群體進行快速、詳細的分析。

優化障礙

缺乏普遍接受的純化外泌體 "黃金標準" 是外泌體研究市場的一大挑戰，促使不同分離方法的產量、純度和污染水平有顯著差異。缺乏標準化使得製備穩定可靠的外泌體變得複雜，而外泌體對於研究應用和治療產品開發都至關重要。在常用的技術中，超速離心法因其能夠根據密度和大小分離外泌體，長期以來被視為一種基礎方法。

目錄

第一章：研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第二章：研究方法

  • 質性研究
    • 一手和二手資料
  • 量化研究
    • 一手和二手資料
  • 依地區劃分的原始調查受訪者
  • 本研究的假設
  • 市場規模估算
  • 資料三角驗證

第三章：摘要整理：全球外泌體研究市場

第四章：全球外泌體研究市場概論

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
    • 全球外泌體CDMO業務
    • 外泌體作為新型態療法的新興作用
  • PESTLE分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場動態與趨勢
    • 成長因素
    • 限制因素
    • 機遇
    • 關鍵因素趨勢
  • COVID-19 對市場成長趨勢的影響評估
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035 年）
  • 競爭格局概覽
    • 市場集中度
    • 公司佔有率分析（基於價值，2025 年）
    • 競爭格局圖

第五章 全球外泌體研究市場分析：依產品與服務劃分

  • 主要發現
  • 市場規模及預測（2020-2035 年）
    • 試劑盒和試劑
    • 設備
    • 服務

第六章 全球外泌體研究市場分析：依適應症

  • 主要觀點
  • 市場規模及預測（2020–2035）
    • 癌症
    • 非癌症

第7章 全球胞外體調查市場分析:各用途

  • 主要的見解
  • 市場規模與預測，2020年～2035年
    • 生物標記
    • 疫苗開發
    • 藥物輸送
    • 化妝品用途
    • 組織再生
    • 其他

第八章 全球外泌體研究市場分析：依最終使用者劃分

  • 主要觀點
  • 市場規模及預測（2020–2035）
    • 學術以及研究機構
    • 製藥和生技公司
    • 醫院和臨床實驗室

第九章 全球外泌體研究市場分析：依地區劃分

  • 主要的見解
  • 市場規模與預測(2020年～2035年)
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第十章：北美外泌體研究市場分析

第十一章：歐洲外泌體研究市場分析

第十二章：亞太地區外泌體研究市場分析

第十三章：中東與非洲外泌體研究市場分析

第14章 南美的胞外體調查市場分析

第15章 美國的胞外體調查市場分析

第16章 中國的胞外體調查市場分析

第17章 日本的胞外體調查市場分析

第18章 企業簡介

  • AMS Biotechnology(Europe)Ltd.
  • Bio-Techne Corporation
  • Lonza
  • Miltenyi Biotec
  • NanoSomiX, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals
  • NX PharmaGen
  • QIAGEN
  • System Biosciences, LLC
  • Thermo Fisher Scientific, Inc.
  • Other prominent players.
簡介目錄
Product Code: AA0223361

The exosome research market is undergoing a significant and definitive pivot, marked by rapid growth and expanding commercial potential. Valued at approximately US$ 280.70 million in 2025, the market is projected to experience remarkable expansion, with revenues anticipated to reach US$ 2,491.42 million by 2035. This impressive growth reflects a compound annual growth rate (CAGR) of 24.4% over the forecast period from 2026 to 2035, underscoring the increasing importance and adoption of exosome technologies across research and therapeutic domains.

One of the primary forces propelling this transformation is the accumulation of validated clinical efficacy data, which strengthens confidence in exosomes as effective therapeutic agents. As more clinical trials demonstrate the safety and therapeutic benefits of exosome-based treatments, stakeholders-including pharmaceutical companies, investors, and regulatory authorities-are increasingly recognizing their potential to address unmet medical needs. Coupled with this clinical validation is the advancement of scalable manufacturing technologies, enabling the production of exosomes in quantities and quality suitable for widespread commercial distribution.

Noteworthy Market Developments

The competitive landscape in the exosome research market is distinctly divided between two key groups: therapeutic pioneers and industrial enablers, each playing a critical role in advancing the field. On the therapeutic front, Capricor Therapeutics and Direct Biologics stand out as the undisputed leaders. Capricor Therapeutics' strategic strength is underscored by its solid financial foundation, boasting a robust cash balance of USD 152 million as it entered 2025. This strong financial position equips Capricor with the necessary resources to support the development and commercialization of its exosome-based therapies.

Meanwhile, Direct Biologics has cemented its dominance through impressive clinical progress, managing a substantial enrollment of 320 patients in their pivotal Phase 3 EXTINGUISH trial. Additionally, Direct Biologics has operated an Expanded Access Program, providing treatment to 103 patients, which highlights the company's commitment to both clinical advancement and patient access.

On the infrastructure side, Lonza and Bio-Techne are setting the pace as essential industrial enablers supporting the exosome research ecosystem. Lonza, in particular, has aggressively established itself as the premier contract development and manufacturing organization (CDMO) for exosome therapeutics. A significant milestone in Lonza's expansion was the acquisition of Codiak BioSciences' exosome manufacturing facility in Lexington, Massachusetts, completed in November 2021.

Core Growth Drivers

The exosome research market is currently propelled by a powerful dual-engine demand that is reshaping its trajectory and driving rapid innovation. On one hand, there is an urgent and growing need for non-invasive "liquid biopsy" biomarkers, which provide clinicians with a revolutionary means of diagnosing and monitoring diseases through simple blood tests or other bodily fluids. Unlike traditional biopsies, which are often invasive, costly, and time-consuming, liquid biopsies harness the unique molecular signatures carried by exosomes to detect disease states early and with high precision. This capability is particularly valuable in oncology, where early detection of cancer can significantly improve patient outcomes.

Emerging Opportunity Trends

One of the most critical trends shaping the exosome research market is the ongoing industrialization of the workflow, marking a profound transformation from artisanal laboratory techniques to standardized, automated engineering processes. Historically, isolating exosomes was considered more of an "art," reliant on manual, labor-intensive methods that required significant expertise and often resulted in variability between batches. Today, this approach is rapidly being replaced by highly reproducible, scalable workflows designed to meet the stringent demands of both clinical research and commercial manufacturing. This shift is clearly evident in the growing adoption of high-throughput flow cytometry technologies, which enable rapid, detailed analysis of exosome populations with increased accuracy and efficiency.

Barriers to Optimization

The absence of a universally accepted "gold standard" for isolating pure exosomes presents a significant challenge within the exosome research market, contributing to considerable variability in yield, purity, and contamination levels across different isolation methods. This lack of standardization complicates efforts to produce consistent and reliable exosome preparations, which are critical for both research applications and the development of therapeutic products. Among the commonly used techniques, ultracentrifugation has long been considered a foundational method due to its ability to separate exosomes based on density and size.

Detailed Market Segmentation

By Product & Services, by 2025, the exosome research market has matured significantly, prompting a decisive shift away from basic, rudimentary precipitation methods toward more advanced and high-purity isolation technologies. This transition reflects the increasing complexity and rigor required in exosome research, especially as the market moves toward clinical and therapeutic applications where product consistency and purity are paramount. The Kits and Reagents segment has maintained its dominant position within the market, capturing a substantial 45.1% share of total revenue.

By Indication, cancer research remains the foundational pillar anchoring the exosome research market, with the oncology segment expected to capture approximately 34.3% of the total market share in 2025. This dominant position reflects the intense focus within the scientific and medical communities on leveraging exosomes to understand, diagnose, and treat various forms of cancer. Exosomes have proven to be invaluable in oncology, particularly as biomarkers that can provide critical insights into tumor biology, disease progression, and treatment response. This steady demand underscores the profound need for innovative tools and therapies capable of addressing the complex challenges posed by cancer.

By End Users, the balance of power in market consumption within the exosome research market has decisively shifted toward the commercial sector, marking a significant change in the dynamics of end-user engagement. By 2025, Pharmaceutical and Biotechnology Companies had emerged as the dominant purchasers, commanding a substantial 49.1% share of the market. This marked overtaking of academic institutions, which historically led demand for exosome research tools and services, reflects a broader trend towards the industrialization and commercialization of exosome technologies.

By Application, while diagnostic applications in the exosome research market continue to generate substantial transaction volumes, the overall value proposition has increasingly shifted toward therapeutic development. In 2025, this shift is particularly evident in the biomarker application segment, which is forecasted to capture over 49.40% of the market share, significantly outperforming the broader market trend. This growth highlights the escalating importance of exosomes as powerful tools not only for disease detection but also for revolutionizing treatment approaches. The biomarker segment's expansion reflects growing confidence in the ability of exosomes to provide highly sensitive and specific indicators of disease states, enabling earlier diagnosis and personalized medicine strategies across a range of medical conditions.

Segment Breakdown

By Product Type

  • Kits & Reagents
  • Antibodies
  • Isolation, Purification, Quantitation Kits & Reagents
  • Other Kits & Reagents
  • Instruments
  • Services

By Indication

  • Cancer
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancers
  • Non-Cancer
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

By Application

  • Biomarkers
  • Vaccine Development
  • Drug delivery
  • Cosmetic Application
  • Tissue Regeneration
  • Other

By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • CDMO
  • Biopharma
  • Hospital & Clinical Testing Laboratories

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Brazil
  • Argentina
  • Rest of South America

Geography Breakdown

  • North America currently commands an impressive 53.10% share of the global exosome research market, a dominance that reflects a uniquely synchronized regulatory and financial ecosystem that few competitors worldwide can rival. This leadership position is not merely the result of scientific expertise or technological innovation but stems from a well-coordinated framework where regulatory agencies and capital markets work in tandem to accelerate the development and commercialization of exosome-based therapies. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping this environment by providing clear regulatory pathways and predictable timelines, which in turn reduce uncertainty for developers and investors.
  • Complementing the regulatory support is the availability of immense financial liquidity within North American capital markets, which provides the substantial funding necessary to sustain the costly and lengthy process of drug development. Capricor Therapeutics exemplifies this financial strength, reporting a robust cash balance of USD 152 million dedicated to supporting its research pipeline. This level of funding enables companies to invest heavily in clinical trials, manufacturing capacity, and commercialization efforts without the immediate pressure of capital constraints.

Leading Market Participants

  • AMS Biotechnology (Europe) Ltd.
  • Bio-Techne Corporation
  • Lonza
  • Miltenyi Biotec
  • NanoSomiX, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals
  • NX PharmaGen
  • QIAGEN
  • System Biosciences, LLC
  • Thermo Fisher Scientific, Inc.
  • Other prominent players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Exosome Research Market

Chapter 4. Global Exosome Research Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Exosome CDMO Business around the World
    • 4.2.2. The emerging role of exosomes as novel therapeutics
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunity
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2035
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Global Exosome Research Market Analysis, By Product & Service

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 5.2.1. Kits & Reagents
      • 5.2.1.1. Antibodies
      • 5.2.1.2. Isolation, Purification, Quantitation Kits & Reagents
      • 5.2.1.3. Other Kits & Reagents
    • 5.2.2. Instruments
    • 5.2.3. Services

Chapter 6. Global Exosome Research Market Analysis, By Indication

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 6.2.1. Cancer
      • 6.2.1.1. Lung Cancer
      • 6.2.1.2. Breast Cancer
      • 6.2.1.3. Prostate Cancer
      • 6.2.1.4. Colorectal Cancer
      • 6.2.1.5. Other Cancers
    • 6.2.2. Non-Cancer
      • 6.2.2.1. Neurodegenerative Diseases
      • 6.2.2.2. Cardiovascular Diseases
      • 6.2.2.3. Infectious Diseases
      • 6.2.2.4. Others

Chapter 7. Global Exosome Research Market Analysis, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 7.2.1. Biomarkers
    • 7.2.2. Vaccine Development
    • 7.2.3. Drug delivery
    • 7.2.4. Cosmetic Application
    • 7.2.5. Tissue Regeneration
    • 7.2.6. Other

Chapter 8. Global Exosome Research Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 8.2.1. Academic & Research Institutes
    • 8.2.2. Pharmaceutical & Biotechnology Companies
      • 8.2.2.1. CDMO
      • 8.2.2.2. Biopharma
    • 8.2.3. Hospital & Clinical Testing Laboratories

Chapter 9. Global Exosome Research Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Exosome Research Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 10.2.1. By Product & Service
    • 10.2.2. By Indication
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. Europe Exosome Research Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 11.2.1. By Product & Service
    • 11.2.2. By Indication
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country

Chapter 12. Asia Pacific Exosome Research Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 12.2.1. By Product & Service
    • 12.2.2. By Indication
    • 12.2.3. By Application
    • 12.2.4. By End User
    • 12.2.5. By Country

Chapter 13. Middle East and Africa Exosome Research Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 13.2.1. By Product & Service
    • 13.2.2. By Indication
    • 13.2.3. By Application
    • 13.2.4. By End User
    • 13.2.5. By Country

Chapter 14. South America Exosome Research Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 14.2.1. By Product & Service
    • 14.2.2. By Indication
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. The U.S Exosome Research Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 15.2.1. By Product & Service
    • 15.2.2. By Indication
    • 15.2.3. By Application
    • 15.2.4. By End User

Chapter 16. China Exosome Research Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 16.2.1. By Product & Service
    • 16.2.2. By Indication
    • 16.2.3. By Application
    • 16.2.4. By End User

Chapter 17. Japan Exosome Research Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2035 (US$ Mn)
    • 17.2.1. By Product & Service
    • 17.2.2. By Indication
    • 17.2.3. By Application
    • 17.2.4. By End User

Chapter 18. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 18.1. AMS Biotechnology (Europe) Ltd.
  • 18.2. Bio-Techne Corporation
  • 18.3. Lonza
  • 18.4. Miltenyi Biotec
  • 18.5. NanoSomiX, Inc.
  • 18.6. Norgen Biotek Corp.
  • 18.7. Novus Biologicals
  • 18.8. NX PharmaGen
  • 18.9. QIAGEN
  • 18.10. System Biosciences, LLC
  • 18.11. Thermo Fisher Scientific, Inc.
  • 18.12. Other prominent players.